Pre-existing donor-specific HLA antibodies in patients undergoing HLA-mismatched SCT have increasingly been recognized as a risk factor for primary graft failure. However, the clinical implications of the presence of HLA antibodies in donors remain unknown. We prospectively examined 123 related donors for the presence of HLA antibodies by using a Luminex-based single antigen assay. Of these, 1/57 (1.8%) male, 6/27 (22%) parous female and 0/39 (0%) nonparous female donors were HLA antibody-positive. Then, we determined the presence of HLA antibodies in seven patients who received SCT from antibodypositive donors. Of these, four became HLA antibody-positive after SCT. The specificities of the antibodies that emerged in the patients closely resembled those of the antibodies found in the donors, indicating their production by donor-derived plasma cells. Moreover, the kinetics of the HLA antibody levels were similar in all four patients: levels started increasing within 1 week after SCT and peaked at days 10 --21, followed by a gradual decrease. These results suggest that donor-derived HLA antibody production frequently occurs in patients undergoing SCT from antibody-positive donors. Further studies are warranted for clarifying the clinical significance of donor-derived HLA antibodies, including the role of these antibodies in post transplant platelet transfusion refractoriness.
INTRODUCTION
Pre-existing donor-specific HLA antibodies in patients have been increasingly recognized as a risk factor for primary graft failure after HLA-mismatched SCT, 1 including unrelated SCT, 2,3 cord blood transplantation 4, 5 or HLA-haploidentical SCT from family donors (haplo-SCT). 6, 7 However, the clinical implications of the presence of HLA antibodies in donors remain unknown. Because HLA antibodies are detected in approximately a quarter of all parous blood donors, 8 SCT from HLA antibody-positive donors are assumed not to be rare events.
Antibody-mediated hemolysis, the so-called 'passenger lymphocyte syndrome', occasionally occurs 1 --2 weeks after minor ABO-incompatible SCT. 9 --11 It is believed that immunocompetent donor B lymphocytes transferred passively with grafts differentiate into antibody-producing cells that produce anti-A and/or anti-B antibodies. Antibodies bind to the recipient's RBCs and cause hemolysis. The time interval between transplantation and onset of hemolysis is considered to correspond to the terminal maturation of the passenger lymphocytes into antibody-producing cells. Moreover, episodes of passenger lymphocyte syndrome due to alloantibodies directed to other blood groups (such as Rh) have also been reported. 12 In a similar manner, B lymphocytes transferred with grafts from HLA antibody-positive do nors may differentiate into plasma cells and produce HLA antibodies. These HLA antibodies potentially bind to transfused platelets expressing the corresponding HLA antigens, thereby causing post transplant platelet transfusion refractoriness. To test this hypothesis, we investigated the presence of HLA antibodies in donors and in patients who received SCT from antibody-positive donors.
SUBJECTS AND METHODS
This study was approved by the Institutional Review Board of the Hyogo College of Medicine. All donors and patients provided informed consent before participating in the study.
Donors
Between June 2008 and October 2010, 123 consecutive donors (57 males and 66 females) for consecutive related SCT were prospectively screened for HLA antibodies (Table 1) . Of 66 female donors, 27 were parous at a median age of 38 (range, 24 --60) years and 39 were nonparous at a median age of 28 (range, 13 --55) years. None of the donors had received blood transfusion or transplantation. In all, 18 donors donated BM and 105 donors donated PBSC. Because most patients undergoing SCT at our institute had been referred from other hospitals where patients could not have been paired with matched siblings or matched unrelated donors, most of the donors were HLA-haploidentical siblings, parents or offspring. Thus, the majority of donors had HLA 2 or 3 antigen mismatches in A, B and DR loci in the graft-versus-host direction.
Patients and transplantation protocols
From 123 donors, 111 patients received allogeneic SCT in a total of 127 times (12 patients received a second or later SCT from a different donor and 4 patients received second or later SCT from the same donor). Following myeloablative and reduced-intensity conditioning regimens, 29 and 98 SCT were performed, respectively. Institutional protocols for SCT from HLA 2 --3 antigen-mismatched donors either with myeloablative or with reduced-intensity conditioning have been described previously. 13, 14 None of the patients received T-cell-depleted graft. Of note, GVHD prophylaxis for HLA 2 --3 antigen-mismatched SCT was intensified by using a combination of tacrolimus, methotrexate, mycophenolate mofetil (15 mg/kg per day), and methylprednisolone (2 mg/kg per day) for myeloablative SCT, and tacrolimus and methylprednisolone (1 mg/kg per day) for reduced-intensity SCT. Moreover, low doses of anti-T-lymphocyte globulin (ATG-Fresenius; 2 mg/kg for 4 days on days À4 to À1) or antithymocyte globulin (Thymoglobulin; 0.5--1 mg/kg for 4 days on days À4 to À1) were included in reduced-intensity conditioning. In general, BM was the stem cell source for SCT with myeloablative conditioning, whereas PBSC were the stem cell source for SCT with reduced-intensity conditioning.
Measurement of HLA antibodies
The methodology used for the measurement of HLA antibody levels has been described previously. 7 Briefly, donor plasma/serum was screened for class I (that is, HLA-A/B/C) and class II (that is, HLA-DR/DP/DQ) HLA IgG antibodies with LABScreen PRA (One Lambda, Canoga Park, CA, USA). Samples with median fluorescence intensity (MFI) 4500 were further tested for the specificity of the antibody using a LABScreen Single Antigen kit (One Lambda). Fluorescence was measured with a Luminex 100 flow analyzer (Luminex, Austin, TX, USA), and the data were analyzed with the LABScan 100 software (One Lambda). All donors and patients were tested for HLA antibodies before SCT. Patients who underwent SCT from HLA antibody-positive donors were serially examined for antibodies for at least 2 months after SCT.
Definitions
For donors, HLA antibody positivity was defined as the presence of HLA antibodies with an MFI 41000 in the LABScreen Single Antigen analysis; MFI values of 500 --1000 were indicative of a weak presence of HLA antibodies. Previous studies have shown that this sensitive assay employing recombinant HLA antigens can result in a frequent detection of antibodies directed against a limited number of rare HLA antigens in nontransfused males and even in cord blood. 15, 16 These antibodies have been termed 'natural antibodies', and the majority of targeted epitopes consist of hidden amino acids that are believed to be inaccessible in the intact form of the HLA antigens. 16 Indeed, natural antibodies detected in renal allograft recipients were not predictive of graft failure. 17 Because these antibodies are unlikely to have clinical implications, we distinguished natural antibodies as being different from HLA antibodies (alloimmunized antibodies). Natural antibodies were defined as antibodies that target rare HLA antigen(s) in the Japanese population and do not crossreact with other HLA antigens belonging to the same crossreactive group. 18 For the patients who received SCT, HLA antibody positivity was defined as the presence of HLA antibodies with MFI 43000 (one test) or MFI 42000 (two consecutive tests). Higher MFI threshold levels were applied to patients undergoing SCT, as compared with donors, because transient HLA antibodies with low MFI levels are often detected in the former, possibly due to an interaction of antithymocyte globulin or the presence of contaminating antibodies in the blood products, including fresh --frozen plasma (data not shown).
RESULTS

HLA antibodies in donors
Among the donors, 1 out of 57 males (1.8%), 6 out of 27 parous females (22%) and none of the 39 nonparous females (0%) were determined to be HLA antibody-positive. HLA antibody production in a 16-year-old male donor was possibly due to vaccination, 19 ,20 because he had not been transfused or received transplantation. Among seven antibody-positive donors, two donors had HLA antibodies corresponding to recipient HLA antigens (recipient-specific antibodies, RSA). In total, 10 donors were determined to be non-alloimmunized antibody (natural antibody)-positive.
Antibodies in patients who underwent SCT from HLA antibodypositive or natural antibody-positive donors Among the seven patients, who received BMT following myeloablative conditioning (n ¼ 2) and PBSCT following reducedintensity conditioning (n ¼ 5) from HLA antibody-positive donors, four patients became HLA antibody-positive after SCT. Of the remaining three patients, who were HLA antibody-negative after SCT, one showed transient low MFI levels of HLA antibodies with specificities similar to those of antibodies present in the donor. However, MFI values did not meet the criteria for HLA antibody positivity used in this study. One patient died on day 14 with multiple organ failure, and the other patient remained HLA antibody-negative.
The characteristics of the four cases (donors and patients) who became HLA antibody-positive following SCT are detailed in Table 2 . Two patients underwent BMT following myeloablative conditioning, whereas the two other patients underwent PBSCT following reduced-intensity conditioning. All patients had active disease at the time of SCT, and two had received prior SCT. One patient (no. 2) had pre-existing HLA antibodies before the first SCT, but these antibodies were reduced after the first SCT and were negative at the time of the second SCT from an HLA antibody-positive donor.
The specificities of class I HLA antibodies found in the donors and those that emerged in patients after SCT were compared ( Figure 1 ). Almost all antibodies that emerged in the patients, with one exception (antibody to A*24:02 in case no. 1), were present in their donors, including some weakly expressed antibodies. Both the patients who received SCT from RSA-positive donors became antibody-positive (no. 1 and no. 4). Interestingly, RSA and crossreactive antibodies 1 (that is, antibodies against B*40:01 and B*48:01 in patient no. 1) were detected in neither of the patients (Figure 1 ). Besides these antibodies, the spectrum of HLA antibody specificities in the patients appeared slightly narrower than that of antibodies in the donors. In addition, class II antibodies were also detected in two cases (no. 2 and no. 3) in both donors and patients with mostly overlapping specificities (data not shown).
The antibody levels in donors and the kinetics of HLA antibody levels in these four patients after SCT are shown in Figure 2 . The kinetics appeared similar in all the patients: the antibody levels started to increase within 1 week after SCT and peaked between days 10 and 21, followed by a gradual decrease. Peak antibody levels in patients were considerably higher than the antibody levels observed in donors.
Among the 10 patients who received SCT from natural antibody-positive donors, 3 patients became natural antibodypositive, while none became HLA antibody-positive. The specificities of natural antibodies observed in two of these patients following SCT were similar to those in their donors. The kinetics of the natural antibody levels in these two patients were similar to those observed in the patients who became HLA antibodypositive after SCT from HLA antibody-positive donors.
DISCUSSION
In this study, we found that HLA antibodies frequently emerged in patients who underwent SCT from HLA antibody-positive donors. These HLA antibodies were most likely to be produced by donorderived antibody-producing cells because their specificities obviously overlapped with those of the HLA antibodies found in the respective donors.
Frequent detection of HLA antibodies in patients undergoing SCT from antibody-positive donors has been previously reported by Lapierre et al. 21 Although this observation suggested the occurrence of donor-derived HLA antibody production, evidence of donor origin was lacking. However, recently developed solidphase immunoassays, including the Luminex single antigen assays, allow the accurate identification and quantification of specific HLA antibodies, 22 which enable the comparison of the specificity of HLA antibodies between donors and patients. To date, only one report by Hatakeyama et al. 23 demonstrated similar specificities between HLA antibodies that emerged in two patients and those found in their donors. Another case report by Nakazawa et al. 24 showed that HLA antibodies with multiple specificities were detected in a patient undergoing SCT from an antibodypositive donor, but the specificity of antibodies in the donor could not be identified.
We also observed that the kinetics of the HLA antibody levels were similar in all four patients: antibody levels began to increase within 1 week after SCT and peaked between days 10 and 21, followed by a gradual decrease. To our knowledge, this is the first report to demonstrate the detailed kinetics of donor-derived HLA antibodies after SCT, which brings new insight into the mechanisms underlying the generation of antibodies.
Although alloantibody production against blood groups in patients following SCT is widely recognized as 'passenger lymphocyte syndrome', 9 --12 its mechanisms remain poorly understood. In contrast, the mechanisms of the enhancement of HLA antibody production following kidney transplantation in patients with pre-existing donor-specific HLA antibodies have been studied extensively. 25 Interestingly, the reported kinetics of HLA antibody levels in patients following kidney transplantation are remarkably similar to our observations. 26 Antibody levels in half of the donorspecific antibody-positive patients increased significantly on day 10, which led to the characteristic histological changes of acute humoral rejection. Thereafter, antibody levels decreased to baseline levels on day 28. The increase in antibody levels after kidney transplantation is attributable to the conversion of host memory B cells to plasma cells after the stimulation with allograft. In fact, Han et al. 27 demonstrated that CD27 þ cells isolated from the peripheral blood of sensitized patients can be stimulated to produce HLA antibodies, suggesting that HLA antigen-specific memory B cells do exist.
Post transplant HLA antibody production in our patients can be explained in a similar manner. BM or PBSC from antibody-positive donors contain memory B cells that are specific for the epitope of certain HLA antigens. Following SCT, memory B cells differentiate Donor-derived HLA antibody production K Taniguchi et al into plasma cells, resulting in the production of specific HLA antibodies. The narrower specificities of HLA antibodies that emerged in patients as compared with those present in donors along with the less frequent emergence of donor-derived natural antibodies than that of donor-derived HLA antibodies suggest that not all of the memory B-cell clones differentiated into plasma cells. Antigen stimulation (possibly via blood transfusion) may be necessary for the differentiation of memory B cells. In this study, the two patients who underwent BMT following myeloablative conditioning and the two of four patients who underwent PBSCT following reduced-intensity conditioning from HLA antibody-positive donors became HLA antibody-positive. In contrast, the aforementioned study by Lapierre et al. 21 showed that the emergence of HLA antibodies is more frequently observed in patients who underwent PBSCT than in those who underwent BMT. They attributed the result to quantitative and qualitative differences between PBSC and BM grafts: PBSC harvests contain a higher number of B cells, T cells and monocytes than do BM grafts. They also speculated that G-CSF mobilization has a 'priming' effect on B cells, rendering them more susceptible to antigen-induced activation than BM-associated B cells. Although the number of HLA antibody-positive donors in this study was too small to draw any definite conclusions, our findings suggest that B cells present in BM have a similar potential to those present in the G-CSF-mobilized PBSC harvest in differentiating into antibody-producing cells.
Previous reports have suggested a role of donor-derived HLA antibodies in platelet transfusion refractoriness. 23, 24 Interestingly, three of four patients in this study showed a decrease in the platelet count, despite platelet transfusion on the previous day, on at least two occasions after testing HLA antibody-positive. It is difficult to specify the cause of platelet transfusion refractoriness in patients following allo-SCT because multiple factors, including thrombotic microangiopathy and infections, can be responsible for the occurrence of platelet transfusion refractoriness. The clinical relevance of donor-derived HLA antibodies for platelet transfusion refractoriness may be a target for future studies.
Theoretically, donor-derived RSA may affect the clinical course of the patients, such as the risk of relapse and GVHD. Several previous studies have shown that alloantibodies to Y-chromosome-associated minor histocompatibility antigens can frequently be found after sex-mismatched SCT, and this has been correlated with the occurrence of chronic GVHD. 28, 29 In this study, two patients received SCT from RSA-positive donors; both patients became antibody-positive after SCT. Although RSA were detected in neither patient, this may be because the RSA can be absorbed with HLA antigens expressed in the patients' tissues. The clinical relevance of RSA could not be evaluated in this study---the occurrence of chronic GVHD could be evaluated only in one patient who developed it; we consider this a target for our future studies.
This study has several limitations. Although we compared the specificity of the HLA antibodies that emerged in patients with those found in their donors, it may be argued that this is not a formal proof of donor derivation. Theoretically, donor-derived antibodies may be distinguished from recipient-derived antibodies by allotype 30 after isolation of HLA antibodies. However, this is a technically difficult task because of the low titers of specific antibodies. Meanwhile, there are several other hypotheses besides donor-derived antibody production, which could also explain the emergence of HLA antibodies after SCT. First, host residual HLA antigen-specific memory B cells could be re-stimulated at the time of SCT by donor HLA antigens, thereafter producing antibodies. This is unlikely to be true in at least three cases in our study, because they had no pre-existing HLA antibodies before SCT. Second, it is possible that contaminating antibodies be detected in blood products because the Luminex-based single antigen assay is very sensitive. However, the kinetics of the antibody levels excludes this possibility: if contaminating antibodies were present, then the levels should have presented a peak at the time of the first detection. Moreover, we defined a more stringent threshold for the definition of HLA antibody positivity in patients who underwent SCT. This was intended to avoid false positives, which can be caused by the variations in results within or between laboratories by the Luminex-based single antigen assay. Collectively, the antibodies that emerged in the patients were most likely to be produced by donor-derived cells. Other limitations of this study include a small number of the patients who underwent SCT from HLA antibody-positive donors and the particularity of the transplantation protocols used. However, the high frequency of donor-derived HLA antibody production despite the intensified GVHD prophylaxis suggest that it may occur at least at similar frequencies following other types of SCT, including HLA-matched related or unrelated SCT.
In conclusion, our study shows that donor-derived HLA antibody production frequently occurs in patients who receive SCT from antibody-positive donors. Further studies are warranted for clarifying the clinical implications of donor-derived HLA antibodies, including the role of these antibodies in posttransplant platelet transfusion refractoriness.
